Studies on mutational load, immune profile, and response to immune checkpoint inhibition in a BRCA1-deficient tumor models have provided a rationale for clinical studies of combined immune checkpoint blockade in BRCA1-associated TNBC [120]. The gene discussed is BRCA1; the disease is neoplasm.